Correction to: Internal and Emergency Medicine (2022) 17:141–151 10.1007/s11739-021-02790-0
In our published paper [Van Laethem J, Wuyts S, Van Laere S, et al. Antibiotic prescriptions in the context of suspected bacterial respiratory tract superinfections in the COVID-19 era: a retrospective quantitative analysis of antibiotic consumption and identification of antibiotic prescription drivers. Intern Emerg Med. 10.1007/s11739-021-02790-0], an error was made in Table 3, regarding the Defined Daily Doses (DDD) of prescribed antibacterials per 100 bed days for the ward patients. The authors are confident that this error did not disrupt any of the conclusions neither the discussion of this paper. The correct values are presented hereunder:
Table 3.
Information on antibiotic treatment; antibiotic classes are presented according to the Anatomical Therapeutic Chemical (ATC)-classification system (J01 level 2) [13]
| Ward | ICU | Total | |
|---|---|---|---|
| Reasons for initiation of antibiotic treatment (n, %) | |||
| Empirically | 10 (10) | 0 (0) | 8 (5) |
| COPDa | 2 (2) | 6 (8) | 8 (5) |
| Positive microbiological sample | 25 (25) | 11 (16) | 36 (22) |
| Radiological consolidation | 47 (47) | 38 (55) | 85 (51) |
| Persistent/rising fever or inflammation | 3 (3) | 9 (13) | 12 (7) |
| Persistent/rising oxygen need | 2 (2) | 1 (1) | 3 (2) |
| Otherb | 11 (11) | 4 (6) | 15 (9) |
| Information on AB treatment, (median, IQR) | |||
| Number of AB treatments per admission | 1 (0) | 2 (2) | 1 (1) |
| Days of AB treatment per admission | 5 (3) | 8 (9) | 5 (5) |
| Lag time before AB initiation per admission | 6 (6) | 10 (8.8) | 7 (8) |
| Total DDDc (n, %) | 690.7 (45.1) | 841.8 (54.9) | 1532.5 (100) |
| Beta-lactam antibiotics, penicillins | 1.2 (0.2) | 56.8 (6.7) | 58 (3.8) |
| Beta-lactam antibiotics, penicillin, with inhibitor | 622 (90.2) | 473.6 (56.3) | 1095.6 (71.5) |
| Other beta-lactam antibiotics | 30 (4.4) | 188.2 (22.4) | 218.2 (14.2) |
| Sulphonamides and trimethoprim | NAd | 18.5 (2.2) | 18.5 (1.2) |
| Macrolides (azithromycin excluded) | 35.5 (5.1) | 6.5 (0.8) | 42 (2.7) |
| Aminoglycosides | NA | 12.8 (1.5) | 12.8 (0.8) |
| Quinolones | 2 (0.3) | 61.2 (7.3) | 63.2 (4.1) |
| Other antibacterials | NA | 24.2 (2.9) | 24.2 (1.6) |
| DDD/admission | |||
| Betalactam antibiotics, penicillins | 0.004 | 0.611 | 0.135 |
| Penicillins with beta-lactamase inhibitor | 1.851 | 5.092 | 2.554 |
| Other beta-lactam antibiotics | 0.089 | 2.024 | 0.509 |
| Sulphonamides and trimethoprim | 0.199 | 0.043 | |
| Macrolides (azithromycin excluded) | 0.106 | 0.070 | 0.098 |
| Aminoglycosides | 0.138 | 0.030 | |
| Quinolones | 0.006 | 0.658 | 0.147 |
| Other antibacterials | 0.260 | 0.056 | |
| DDD/100 bed days | |||
| Betalactam antibiotics, penicillins | 0.042 | 2.793 | 1.191 |
| Penicillins with beta-lactamase inhibitor | 21.948 | 23.284 | 22.506 |
| Other beta-lactam antibiotics | 1.059 | 9.253 | 4.482 |
| Sulphonamides and trimethoprim | 0.910 | 0.380 | |
| Macrolides (azithromycin excluded) | 1.253 | 0.320 | 0.863 |
| Aminoglycosides | 0.629 | 0.263 | |
| Quinolones | 0.071 | 3.009 | 1.298 |
| Other antibacterials | 1.190 | 0.497 | |
The authors regret this error.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.